Association of Single Nucleotide Polymorphisms with Dyslipidemia in Antiretroviral Exposed HIV Patients: A Case-Control Study in a Ghanaian population

Christian Obirikorang [1], *Emmanuel Acheampong [1,2], Lawrence Quaye [4], Joseph Yorke [5,] Ernestine Kubi Amos-Abanyie [3], Priscilla Abena Akyaw [3], Enoch Odame Anto [1,2], Simon Bannison Bani [4] Evans Adu Asamoah [1], Emmanuella Nsenbah Batu [1]

[1] Department of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana

[2] School of Medical and Health Science, Edith Cowan University, Joondalup, Australia

[3] H3Africa Kidney Disease Research Project, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana

[4] School of Allied Health Sciences, University of Development Studies, Tamale Ghana

[5] Department of Surgery, Komfo Anokye Teaching Hospital, Kumasi

*Corresponding author
Emmanuel Acheampong
Department of Molecular Medicine
School Medical Science
KNUST
emmanuelachea1990@yahoo.com

Abstract

Dyslipidemia is a potential complication of long-term usage of antiretroviral therapy (ART) and also known to be associated with genetic factors. The host genetic variants associated with dyslipidemia HIV patients on ART in Ghana have not been fully explored. A total of 289 HIV-infected patients on stable ART for at least a year and 104 age-matched controls with no history of HIV and dyslipidemia were recruited for the study. Fasting blood was collected into EDTA for lipids measurements. Lipid profiles were determined as a measure of dyslipidemia. There was a significant difference in case-control prevalence for dyslipidemia (31.4% vs. 18.3%, p=0.013). Four candidate Single Nucleotide Polymorphisms (SNPs) from four genes (ABCA1-rs2066714, LDLR-rs6511720, APOA5-rs662799 and DSCAML1-rs10892151) were determined. Genotyping was performed on isolated genomic DNA of study participants using PCR followed by a multiplex Ligation Detection Reaction (LDR). Significantly increased levels of total cholesterol (TC) low-density lipoprotein cholesterol (LDL-C) and triglycerides [TG] were observed in protease inhibitor-based (PI) treated case subjects compared to non-PI-based case subjects. The population frequency of homozygotes for the rare alleles rs6511720 (T/T), rs2066714 (G/G), rs10892151 (T/T) and rs662799 (G/G) were 3.6%, 9.6%, 6.4% and 6.0%, respectively. Adjusted analysis controlling for age, gender and duration of treatment revealed that rare homozygous genotypes for APOA5 (G/G) [aOR=18.74(5.65-54.73), p<0.0001], ABCA1 (G/G) [aOR=3.94(0.86 -17.38), p=0.033] and DSCAML1 (T/T) [aOR=11.46(3.651-43.56), p<0.0001) were significant factors for high TC. Subjects with the T/T genotype for *DSCAML1* (rs10892151) were associated with a high likelihood of raised levels of LDL-C [aOR=3.76(1.43-8.46), p=0.033]. Furthermore, the rare homozygous genotype for *ABCA1* (G/G) [aOR=5.67(3.43-13.54), p<0.0001] and LDLR (T/T) [aOR=4.46(1.86-10.56), p<0.0001) was significantly associated with hypertriglyceridemia. The study has demonstrated the presence of SNPs in four candidate genes among HIV patients exposed to ART in the Ghanaian population. SNPs were found to associate with dyslipidemia. These findings provide baseline information that necessitates a pre-symptomatic strategy for monitoring dyslipidemia in ART-treated HIV patients. There is a need for longitudinal studies to validate a comprehensive number of SNPs and its association with dyslipidemia.

Keywords: Dyslipidemia, Human Immunodeficiency Syndrome, Single Nucleotide Polymorphism

Introduction

Global estimates report 37 million people living with Human Immunodeficiency Virus (HIV), out of which about 26 million reside in Sub-Saharan (SSA) [1]. In Ghana, HIV prevalence among adults aged 15-49 years has declined from about 2.4% in 2013 to 1.6% in 2015 according to the World Bank report [2]. The life expectancy of HIV-infected patients has increased remarkably due to the use of antiretroviral therapy (ART) as a standard of care [3-5]. Unfortunately, long term ART use is associated with a wide spectrum of metabolic disturbances such as lipodystrophy, insulin resistance, and dyslipidemia[6-8]. Dyslipidemia is defined by elevations in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides and decreased high-density lipoprotein cholesterol (HDL-C).

The prevalence of dyslipidemia is reportedly higher in people living with HIV due to the effect of ART in Ghana [12-14]. The severity of dyslipidemia and the typical pattern of the lipid profile differ between and within the classes of antiretroviral (ARV) agents [15]. Lipid abnormalities have been reported to be frequently associated with HIV-infected individuals receiving protease inhibitors (PIs) and treatment-*naïve* HIV-infected patients, suggesting that HIV infection itself has a metabolic deleterious effect. Such reported side effects are not universal to all individuals on ART and may even vary in individuals with comparable ART, demographic, immunologic and virological characteristics [15-17]. This variability suggests that genetic factors and inherited predispositions may have a significant influence on the incidence of metabolic dysfunction [17, 18]. Specifically, a direct association has been observed between higher LDL cholesterol and triglyceride levels and cardiovascular disease progression. In contrast, high HDL cholesterol and apolipoprotein A-I (*APOA-I*) have been directly associated with a better immunological outcome [19].

The exact mechanism of dyslipidemia is not fully understood but is most likely multifactorial with genetic variation being shown to account for about 43-83% of the variability of plasma lipoprotein levels in a normal healthy population [19, 20]. Therefore, from the genetic perspective, HAART-associated hyperlipidemia could be under the influence of various forms of genetic polymorphisms, similar to that in non-HIV adults [21, 22]. Several single nucleotide polymorphisms (SNPs) that could account for a significant portion of the variation of blood lipoprotein concentrations have been identified through recent candidate gene studies and genome-wide association studies (GWAS)[18, 23].

The association between gene polymorphisms that may signal a predisposition to lipid abnormalities and clinical progression of HIV infection has not been thoroughly studied in Africa where the prevalence of HIV is on the increase. SNP prevalence differs by population and at present, numerous SNP-associated dyslipidemia studies among HIV patients have come from non-African countries [18, 24, 25]. No published study has thus far explored the genetic variants and markers associated with dyslipidemia in HIV-infected individuals on HAART in Ghana. This study, therefore, investigated the distribution of SNPs in four candidate genes and resultant associations with plasma lipid levels in Ghanaian HIV-infected patients on HAART. An understanding of the impact of host genetic factors on the prevalence of dyslipidemia in a cohort of HIV-infected individuals on HAART would promote interventions in the scaling up of treatment regimen.

Material and Methods

Study design and subjects

This case-control study comprised HIV-1 infected patients who were on ART regimen for at least one year, with either a PI or non-nucleoside reverse-transcriptase inhibitor (NNRTI) backbone alongside age-matched control subjects with no history of HIV, dyslipidemia, hypertension, and diabetes. The adjuvant antiretroviral drugs were stavudine, lamivudine, and zidovudine with priorities for inclusion being given to participants who consented to undergo biochemical and genetic testing. Pregnant women, patients being treated with lipid-lowering drugs and those with neurological conditions that prevented them from understanding the concept of the research were excluded from the study.

Sample size determination

Using an expected proportion of 0.1 for exposure in control subjects, an assumed odds ratio of 2, a confidence interval of 95%, a power of identifying a significant difference between two groups, and 1:3 ratio, a total of 396 subjects were recruited. This comprised of 289 case subjects and 104 control subjects.

Data collection and biochemical analysis

A structured questionnaire was administered to each patient to obtain demographic information. Details on ARVs, time of diagnosis, duration on and ARVs were obtained from the medical folders of the patients. Fasting blood samples were collected for the analysis of lipid parameters and genomic DNA.

Blood samples were taken after an overnight (12-14 hours) fast into EDTA tubes for biochemical analysis. Fasting lipid panel including total cholesterol (TC), HDL-cholesterol and triglycerides (TG) were measured using Flexor junior (Vital Scientific, Dieren, Netherlands) chemistry autoanalyzer. LDL-C was calculated from the Friedewald's formula, LDL-C= TC- (HDL-C- TG/2.2). Due to the deficit of the Friedewald's equation, those that had triglycerides above 4.52 mmol/L were not included in the study. The NCEP-ATP III criteria were used to define dyslipidemia as reduced HDL (<1.03□mmol/L in males; <1.29□mmol/L in females), raised TG ≥1.7□mmol/L, TC >6.2 mmol/L and LDL-C >3.37 mmol/L or specific treatment for such lipid abnormalities.

Anthropometric and hemodynamic measures

Anthropometric measures such as weight and height were performed using an automated weighing scale. Portable height rod stadiometers were used for height measurements to the nearest centimeter. Body mass index (BMI) was defined as weight (kg)/height (m)^2. Blood pressure was measured using an automated sphygmomanometer (Omron M7 Intelli IT). Three consecutive readings of blood pressure measurements were taken from the patients' right arm and the mean of two closest value was recorded.

Single nucleotide polymorphisms selection and Genotyping

Four candidate SNPs (rs2066714, rs6511720, rs662799, and rs10892151) were selected following a review of PubMed reports of SNPs associated with dyslipidemia among HIV-infected individuals [25-28]. Genomic DNA was isolated from EDTA-collected whole blood samples of study participants using the Qiagen midi kit prep as per manufacturer's protocol.

Genotyping was carried out on isolated genomic DNA of study participants using a multiplex ligation detection reaction (LDR), a sequence-specific genotyping method which has been used efficiently in polymorphism typing and detection of mutations in disease genes [29]. Triplex multiplex reaction assays were setup with products being run on 10% polyacrylamide gel for LDR genotype observation (58 to 90 base pairs). The LDR products differed in sizes of about 8 base pairs

for each triplex (Fig. 1). The runs were controlled with Amelogenin XY (AME XY) to determine a successful reaction and gender-confirming for study participants.

Fig 1. A representative gel depicting a genotyping assay using triplex Ligation Detection Reaction.

As shown in **Figure 1**, allele specific LDR products are assigned by color and size following 10% polyacrylamide gel electrophoresis. Each band as shown in the image represents a specific genotype of each allele. At the bottom of the gel are leftover LDR probes from the reaction mix as represented by shared common bands

Ethical Consideration

The study protocol was approved by the Committee of Human Publication and Research Ethics of the School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. All participants gave written informed consent and were assured that the information gathered was to be used strictly for research and academic purpose only. In addition, respondents were given the freedom to opt-out at any time they thought they could not continue with the study.

Statistical Analysis

The results were expressed as mean ± standard deviation (SD) for continuous variables and as proportions for categorical variables. Allele frequencies were estimated by gene counting. Deviations in the genotype frequencies from the Hardy-Weinberg equilibrium (HWE) were tested using the chi-square (χ^2) analysis. Adjusted multivariate binary logistic models were used to identify SNPs independently associated with lipid abnormalities controlling for age, gender, BMI, and duration of HIV infection. The prevalence ratio (PR) was used as a measure of the association of SNPs with dyslipidemic prevalence instead of odds ratio (OR) among case subjects because of the observed high prevalence of the dyslipidemia, thus providing a better estimate of risk [30, 31]. A p-value of less than 0.05 was considered statistically significant.

Results

As shown in Table 1, there was no significant difference in age between cases and control. There were more females than male in both cases (82.0% vs. 18.0%) and control (69.3% vs. 30.7%). The average duration for treatment among the case subjects was 4 years. Mean levels of diastolic blood pressure were significantly higher in cases compared to control subjects. The weight of the case subjects was significantly higher than control subjects [77.3±14.3 vs. 62.8±13.2, p<0.0001]. All but HDL-cholesterol levels were significant levels in the control subjects compared to case subjects [1.44±0.33 vs. 0.99±0.53, p<0.0001]. Dyslipidaemia was observed in a higher proportion of case subjects compared to control subjects [31.4% vs. 18.3%] with statistical significance (p=0.013)

Table 1: Demographic and lipid parameters of study participants

Variables	Cases n=289	Control (n=104)	P-value
Age (years)	39.7±10.0	38.5±4.41	0.238
Gender [a]			**0.020**
Male	52(18.0%)	32(30.7%)	
Female	237(82.0%)	79(69.3%)	
Duration of treatment	4.32±2.88		
Blood pressure (mmHg)			
Systolic	114.1±16.5	116.0±16.4	0.295
Diastolic	81.1±7.9	78.2±15.8	**0.019**
Weight (kg)	77.3±14.3	62.8±13.2	**<0.0001**
Height (m)	1.60±0.14	1.53±0.15	**<0.0001**
Body mass index (BMI) (kg/m^2)	32.2±17.5	26.8±11.6	**0.004**
Lipid parameters (mmol/L)			
Total Cholesterol	4.58±1.18	4.33±0.96	**0.032**
Triglycerides	1.48±0.72	1.22±0.48	**0.008**
HDL-Cholesterol	0.99±0.53	1.44±0.33	**<0.0001**
LDL-Cholesterol	3.01±1.18	2.90±1.15	**0.017**
VLDL-Cholesterol	0.61±0.02	0.20±0.08	**<0.0001**
Coronary Risk	6.37±0.33	3.29±0.95	**<0.0001**
Dyslipidaemia n (%)	90(31.4%)	19(18.3%)	**0.013**
Hypertriglyceridemia	45(15.6%)	17(16.4%)	0.876
Hypercholesterolemia	72(24.9%)	15(14.4%)	**0.028**
Low HDL-Cholesterol	205(71.9%)	14(13.5%)	**<0.0001**

As shown in **Table 2,** the genotype distribution of the four SNPs did not deviate from the Hardy-Weinberg equation. The percentage of the population who had the rare homozygote alleles for rs6511720 (T/T), rs2066714 (G/G), and rs10892151 (T/T) and rs662799 (G/G) were 3.5%, 10.0%, 6.6% and 5.9% with no case-control significant difference. However, chi-square analysis reveals a significant difference between cases and control for rs662799 (G/G) (p=0.021).

Table 2: Genotypic and Allelic frequencies of polymorphisms of the Studied Population

Polymorphisms	Cases 289 n (%)	Allelic frequency		Control 104 n (%)	Allelic frequency		#P-value
LDLR (rs6511720) G>T		G	T		G	T	0.786
G/G	220 (76.1)	0.86	0.14	82(78.8)	0.88	0.12	
G/T	59 (20.4)			18(17.3)			
T/T	10(3.5)			4(3.9)			
ABCA1 (rs2066714) A>G		G	A		G	A	0.158
G/G	29 (10.0)	0.76	0.24	5(4.8)	0.84	0.16	
A/G	77 (26.6)			24(23.1)			
A/A	183 (63.3)			75(72.1)			
DSCAML1 (rs10892151) C>T		C	T		C	T	0.204
C/C	196 (67.8)	.81	0.19	80(76.9)	0.87	0.13	
C/T	74 (25.6)			20(19.2)			
T/T	19 (6.6)			4(3.9)			
							0.021
APOA5 (rs662799) A>G		A	G		A	G	
A/A	198(68.5)	.82	0.18	86(82.7)	0.89	0.11	
A/G	74 (25.6)			14(13.5)			

G/G	17(5.9)	4(3.9)

#P-value represents chi-square test to compare allelic frequency between cases and control subjects

Total Cholesterol (TC)

The mean levels of TC were significantly associated with *LDLR, ABCA1, DSCAML1* and *APOA5* polymorphisms (p<0.05). Individuals with the homozygous genotype for *LDLR* (rs6511720 T/T) had significantly higher level of TC compared to the combined heterozygous and non-carriers genotype (GG/GT) (p<0.001), Similar pattern were observed for *DSCAML1* (rs10892151) (p=0.0136), *APOA5* (rs662799) (p=0.0012) and *ABCA1* (rs2066714) (p=0.0109) polymorphism respectively **[Table 3].**

Triglycerides (TG)

The *DSCAML1* C>T (rs10892151) polymorphisms were significantly associated with TG levels. The homozygous rare genotype showed significantly higher levels of TG compared to the common genotypes (CC/CT) respectively. No significance difference was observed between TG regarding *ABCA1* G>A (rs2066714) (p=0.3924) and *APOA5* A>G (rs662799) (p=0.6781) and *LDLR* (rs6511720 T/T) (p=0.0588) when genotypes were compared **[Table 3].**

HDL Cholesterol (HDL-C)

With regards to *LDLR* G>T (rs6511720), *DSCAML1* C>T (rs10892151) ABCA1 A>G (rs2066714) and APOA5 A>G (rs662799) polymorphisms, there was no significant difference in HDL-C levels between the polymorphisms among the studied participants (p>0.05) **[Table 3].**

LDL Cholesterol (LDL-C)

The average LDL-C levels were associated with LDLR G>T (rs6511720) (p=0.0008), DSCAML1 C>T (rs10892151) (p=0.0412), APOA5 A>G (rs662799) (p=0.0082) and ABCA1 (rs2066714 A>G) (p=0.0283). Thus, increased LDL-C levels were observed in rare-allele subjects for all the SNPS compared to subjects with heterozygous and homogenous genotypes together **[Table 3].**

Polymorphisms	Total Cholesterol (mmol/L)	Triglycerides (mmol/L)	HDL-Cholesterol (mmol/L)	LDL-Cholesterol (mmol/L)
LDLR (rs6511720) G>T				
GG/GT	4.29±0.89	1.41±0.66	0.99±0.53	2.93±1.07

Table 3: Comparison of lipid parameters among case subjects based on polymorphism

T/T	5.52±0.83	1.83±1.30	1.04±0.061	4.12±1.72
p-value	**<0.0001**	0.0588	0.7543	**0.0008**
ABCA1 (rs2066714)				
A>G				
AA/AG	4.28±0.91	1.41±0.68	1.04±0.53	2.92±1.10
G/G	4.74±1.156	1.52±0.785	0.94±0.47	3.39±1.153
p-value	**0.0109**	0.3924	0.5615	**0.0283**
DSCAML1 (rs10892151)				
C>T				
CC/CT	4.29±0.9	1.38±0.62	0.99±0.53	2.94±1.10
T/T	4.89±1.34	2.02±1.23	0.97±0.565	3.47±1.13
p-value	**0.0136**	**<0.0001**	0.8719	**0.0412**
APOA5 (rs662799)				
A>G				
AA/AG	4.28±0.92	1.42±0.69	0.98±0.50	2.93±1.09
G/G	5.05±1.216	1.49±0.7704	1.08±0.3751	3.66±1.21
p-value	**0.0012**	0.6781	0.4834	**0.0082**

Data is presented as Mean ± Standard Deviation, p<0.05=statistically significant

Table 4 shows the non-adjusted analysis of the association of SNPs with dyslipidemia among case subject.

Subjects with T/T genotype for LDLR G>T (rs6511720) polymorphisms had a prevalence of dyslipidemia 3.46 times greater than non-dyslipidemic subjects. This association was statistically significant; at a level of 5%.

The strength of this association was even greater in subjects with the homozygous genotype for APOA5 A>G (rs662799) polymorphisms [G/G] [PR=3.83(1.34-11.33, p=0.017].

Table 4: Non-adjusted analysis of the association of SNPs with the dyslipidemic prevalence

Polymorphisms	Dyslipidaemia		PR (95% CI)	P-value
	Yes (n, %)	No (n, %)		
LDLR (rs6511720) G>T				
G/G	61(67.8%)	160(80.4%)	1	
G/T	24(26.7%)	35(17.6%)	1.87(1.02-3.32)	0.127
T/T	5(5.6%)	4 (2.0%)	3.46(0.95-11.09)	**0.044**
ABCA1 (rs2066714) A>G				
G/G	54(60.0%)	128(64.3%)	1	
A/G	23(25.6%))	53(26.6%)	1.04(0.59-1.93)	0.882
A/A	13(14.4%)	18(9.1%)	1.61(0.79-3.74)	0.210
DSCAML1 (rs10892151) C>T				
C/C	60(66.7%)	136(68.4%)	1	
C/T	24(26.7%)	30(15.1%)	1.51(0.98-3.27)	0.073
T/T	6(6.6%)	18(9.1%)	0.46(0.29-1.96)	0.644
APOA5 (rs662799) A>G				
A/A	56(62.2%)	143(71.9%)	1	
A/G	25(27.8%)	48(24.1%)	1.23(0.74-2.38)	0.370
G/G	9(10.0%)	6(3.0%)	3.83(1.34-11.33)	**0.017**

PR=Prevalence ratio

Table 5 shows the association of demographic factors, antiretroviral therapy, and SNPs with lipid abnormalities. Individuals with the homozygous genotype for *APOA5* (G/G) [aOR=18.74(5.65-54.73), p<0.0001], *ABCA1* (G/G) [aOR=3.94(0.86-17.38), p=0.028] and *DSCAML1* (T/T) [PRR=11.46(3.65-43.56), p<0.0001) and *LDLR* (rs6511720) G>T [aOR=4.54(1.34-76, p=0.030) were more likely to have high levels of TC levels. Moreover, subjects with T/T genotype for *DSCAML1* (rs10892151) C>T polymorphism were associated with a higher likelihood of high levels

of LDL-C [aOR=3.76(1.43-8.46), p=0.018]. Furthermore, the homozygous genotype for *ABCA1* (G/G) [aOR=5.67(3.43-10.56), p<0.0001] and LDLR (T/T) [aOR=4.46(1.86-10.56), p<0.0001)) were significantly associated with hypertriglyceridemia. Results from the study did not find any significant association between the four SNPs and low HDL levels among studied subjects (p>0.05)

Table 5: Association of demographic factors, antiretroviral therapy, and SNPs with lipid abnormalities

Variables	Hypercholesterolemia aOR (95% CI)	Hypertriglyceridemia aOR (95% CI)	Low HDL -C aOR (95% CI)	High-LDL-C aOR (95% CI)
Model 1				
Male gender	0.49(0.24-3.18) *	0.76(0.29-3.43) *	0.67(1.32-0.46) **	1.01(0.62-1.99) *
Duration of ART (per year)	1.18(0.84-2.43) *	0.97(0.67-1.45) *	0.88(0.76-1.98) **	1.18(0.93-2.24)
PI -based treatment	1.43(0.84-19.4) *	2.32(0.98-12.36) *	1.58(0.54-6.84)	5.54(0.87-29.53)
APOA5 (rs662799) G/G	15.34(5.56-44.73) ***	1.58(0.17-4.46) *	2.20(0.55-6.78)	1.29(0.36-3.68)
LDLR (rs6511720) T/T	2.45(1.02.-14.76) **	4.02(1.23-11.37) ***	1.87(0.45-3.69)	1.59(0.62-4.11)
ABCA1 (rs2066714) G/G	3.01(0.65-14.89) **	4.87(2.40-11.44) ***	1.43(0.32-3.68)	1.21(0.37-3.45)
DSCAML1 (rs10892151) T/T	10.43(2.56-24.74) ***	1.61(0.12-4.79) *	1.53(0.87-5.04)	3.84(1.54-7.42) **
Model 2				
Duration of ART (per year)	1.13(0.67-3.44) *	0.89(0.74-1.27) *	0.98(0.76-1.10) **	1.21(0.90-2.14)
PI -based treatment	1.02(0.84-19.4) *	2.76(0.98-12.36) *	1.92(0.32-7.34)	5.67(0.76-35.97)
APOA5 (rs662799) G/G	14.32(3.22-36.46) ***	1.67(0.64-7.69) *	2.24(0.55-6.78)	1.15(0.45-4.33)
LDLR (rs6511720) T/T	2.23(1.54-10.87) **	4.84(1.86-11.49) ***	1.72(0.63-3.98)	1.49(0.81-4.20)
ABCA1 (rs2066714) G/G	3.49(0.66-19.87) **	3.76(2.45-12.44) ***	1.76(0.56-4.37)	1.11(0.13-3.90)
DSCAML1 (rs10892151) T/T	9.67(3.87-38.66) ***	1.89(0.13-4.90) *	1.44(0.92-4.61)	4.75(1.32-7.83) **
Model 3				
APOA5 (rs662799) G/G	18.74(5.65-54.73) ***	0.67(0.20-3.02) *	2.24(0.55-6.78)	1.25(0.40-3.23)
LDLR (rs6511720) T/T	.54(1.34-13.76) **	4.46(1.86-10.56) ***	1.72(0.63-3.98)	1.52(0.68-3.01)
ABCA1 (rs2066714) G/G	3.94(0.86-17.38) **	5.67(3.43-13.54) ***	1.53(0.56-3.39)	1.01(0.461-2.45)
DSCAML1 (rs10892151) T/T	11.46(3.65-43.56) ***	1.65(0.12-3.78) *	1.48(0.96-4.90)	3.76(1.43-8.46) **

aOR=Adjusted odds ratio, TC Total cholesterol, TG= Triglycerides, HDL-C=High Density Lipoprotein Cholesterol, LDL-C=Low Density Lipoprotein Cholesterol, P<0.05=Statistically Significant

Model 1: adjusted multivariate analysis controlling for age and BMI

Model 2: adjusted multivariate analysis controlling for age, gender and BMI

Model 3: adjusted multivariate analysis controlling for age, gender, BMI and duration of treatment

*p>0.05,

**p<0.05,

***p<0.005

Discussion

Long term usage of ART has been implicated in several metabolic effects including dyslipidemia. However, this side effect varies among individuals on ART with comparable clinical and demographic characteristics. As such, inherited predispositions and genetic factors have been implicated in the cause of this metabolic alteration. This study, therefore, assessed the prevalence of SNPs and its association with dyslipidemia in HIV patients on ART in Ghana. Four candidate SNPs (rs2066714, rs6511720, rs662799, and rs10892151) reviewed from PubMed were analyzed for associations with dyslipidemia among HIV-infected individuals.

Several studies have shown an association between dyslipidemia and HIV on ART [32, 33]. In this study, the prevalence rate of dyslipidemia among HIV patients on ART was 31.4% with low HDL-C levels being the commonest lipid abnormality (71.9%), followed by hypercholesterolemia (24.9%) and 15.6% had hypertriglyceridemia. The observed prevalence of dyslipidemia is comparable to the range of reports from previous studies by Obirikorang et al.,[12] and Ngala et al [13] in Ghana and Kodogo et al., [13] in Zimbabwe. However, it is lower compared 78.9% prevalence rate reported by Limas et al, [34] in a cross-sectional study among Brazilian HIV individuals on ART. Furthermore, our findings of low HDL-C and high total cholesterol and LDL-C among HIV patients on ART is consistent with other studies [35, 36]. Results from the study revealed that subjects who received PI-based treatment had significantly increased levels of total cholesterol, LDL cholesterol and triglycerides compared to non-PI-based subjects. This is consistent with several case reports [37, 38] and cross-sectional studies [39, 40] which have reported that PI exposures are associated with hypercholesterolemia and hypertriglyceridemia.

Our study demonstrated that the presence of the homozygous recessive/mutant genes for *LDLR, ABCA1, DSCAML1* and *APOA5* genotypes among our study participants were very low [Table 2]. Similar low frequencies in APOA5 and LDLR homologous mutant genes were reported by Lazzaretti et al., [18] in a cross-sectional study among HIV-infected patients on ART in the Brazilians population. Genome-wide associations studies have identified LDL-R SNP rs6511720 (G>T), which is located in intron-1 of the gene, to be associated with lower plasma levels of LDL-C and a lower risk of CHD [28]. Data from the GLGC consortium suggested that *LDLR* rs6511720 minor allele is prevalent in about 10% of the population and have established that the allele is protective, being associated with lower levels of LDL-C [41].

A longitudinal study conducted by Rotgar et al. [42] validated the contribution of 42 SNPs to dyslipidemia among HIV-infected population treated with ART, The authors reported that the degree of the contribution of SNPs and ART to dyslipidemia are similar and therefore genetic information should be considered in addition to the dyslipidemic effect of ART agents[42]. Results from the study revealed that individual with rs6511720 T/T genotype recorded increased levels of TC, TG, and LDL-C compared to non-carriers and heterozygous combined rs6511720 GG/GT [Table 3]. A study by Lazzaretti et al., [18] reported that *LDLR* intron 19G>T (rs6511720) did not contribute to the plasma lipid levels in their dataset, and hence may reflect a limited effect of this SNPs in HIV-infected patients. The inconsistency could be due to different geographical settings and thereby calls for more research in these SNPs among African descendants.

In this study, ABCA1 (rs2066714) G/G genotype was significantly associated with increased levels of TC and LDL-C compared to the common allele (AA/AG) genotypes and low HDL-C was the commonest lipid abnormality among the HIV patients. This observation could be explained by the observation that almost half of the subjects carried the ABCA1 (rs2066714) G/G or A/G mutant genotypes [Table 2] which is associated with familial HDL deficiency. Moreover, ABCA1 mediates the efflux of cellular cholesterol and phospholipids unto ApoA-I and thereby plays a central role in both regulating cellular cholesterol homeostasis, and forming HDL[43, 44].

DSCAML1 (rs10892151) SNP in this study had increased levels of TC, TG, and LDL-c in T/T genotype individuals compared with the other genotypes. Further analysis indicated that individuals with the homologous minor recessive gene (carriers) (T/T) were more likely to have increased levels of TC and LDL-C. These observed findings are in parallel with previous reports by Aragones et al., [25] who reported a strong association between the expression of the rs10892151 T allelic variant and dyslipidemia, mostly hypertriglyceridemia and depressed HDL-cholesterol levels. In addition, Pollin et al., [45] observed that rs10892151 T carriers had lower fasting and postprandial serum triglycerides values than non-carriers, and they found a linkage disequilibrium with an APOC3 null mutation, which was likely the result of a founder effect in their high-fat feeding intervention study. Evidence provided in literature shows that carriers of this null mutation have low circulating apolipoprotein (Apo) C-III levels and reduced fasting and post-prandial triglyceride concentrations [45], which is likely due to the well-established function of Apo C-III as an inhibitor of lipoprotein lipase[46].

This current study showed that carriers of the minor allelic variant of the *APOA5* (rs662799) A>G SNP gene, either being homologous(G/G) has significantly increased levels of TC and LDL

cholesterol compared to wild type and heterozygote combined (AA/AG). The rs662799 is a SNP in the *APOA5* gene. This SNP is associated with elevated plasma triglyceride levels. Two polymorphisms in the *APOA5* gene, −1131T>C and S19W (56C>G), have already been shown to be associated with elevated triglyceride levels in different populations[47, 48]. This study, however, considered the *APOA5* (rs662799) A>G variant and found that HIV individuals with at least one G allele had higher TC and LDL cholesterol levels.

 Lazzaretti et al, [18] reported that *APOA5* −1131T>C (rs662799) was associated with plasma triglycerides (TG) and low-density lipoprotein cholesterol levels (LDL-C) as well as high-density-lipoprotein cholesterol levels. To our knowledge, this study is the first to investigate the *APOA5* (rs662799) A>G variant in HIV patients in a Ghanaian population. Another study by Echeverria et al., [49] reported that polymorphisms in genes associated with the development of atherogenic dyslipidemia, especially variants in the *APOA5* gene (rs3135506 and rs662799), can influence the circulating CD4 T-cell levels in chronically HIV-infected patients. Although this study, did not investigate the CD4 levels in association with the SNP variants, it has provided proof of the effect of *APOA5* (rs662799) A>G and associated dyslipidemia in HIV patients on ART.

This study has strength in it possibly being the first study to assess the prevalence of SNPs and its association with dyslipidemia in the Ghanaian population as a proof of concept. However, our study is limit by the fact that the number of investigated polymorphisms is not comprehensive, notwithstanding, this is a baseline study for future exploratory analysis of SNPs and its association with dyslipidemia among HIV patients on ART in Ghana.

Conclusion

This study has highlighted the evidence that SNPs in four candidate genes are present in HIV patients exposed to ART in the Ghanaian population. Dyslipidemia remains prevalent among HIV patients. SNPs were found to associate with dyslipidemia This finding provides baseline information that necessitates a pre-symptomatic strategy for monitoring dyslipidemia in ART-treated HIV patients Findings from this study should be validated in longitudinal case-control study considering the disease and its therapeutic implications. The candidate SNP if validated will help in serving as potential biomarkers to detect individuals at risk for dyslipidemia.

Acknowledgment

The authors thank Prof. David T. Burke and Jodi Wilkowski (Department of Human Genetics, University of Michigan Medical School, Michigan, USA) for immense help. We also wish to express our profound gratitude to all HIV patients who actively participated in this study.

Data Availability

The data used to support the findings of this study are part of an ongoing project and are available upon request.

Conflict of interest

The authors declare no conflict of interest

References

1. Piot P, Bartos M, Ghys PD, Walker N, Schwartländer B: **The global impact of HIV/AIDS**. *Nature* 2001, **410**(6831):968.
2. **Global AIDS Update 2017; July 2017. UNAIDS. AIDSinfo website; accessed July 2017,**
3. Monsuez J-J, Charniot J-C, Escaut L, Teicher E, Wyplosz B, Couzigou C, Vignat N, Vittecoq D: **HIV-associated vascular diseases: structural and functional changes, clinical implications**. *International journal of cardiology* 2009, **133**(3):293-306.
4. Taiwo B, Li X, Palella F, Jacobson L, Margolick J, Detels R, Rinaldo C, Phair J: **Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART**. *HIV medicine* 2009, **10**(10):657-660.
5. Marins JRP, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, Chequer P, Teixeira PR, Hearst N: **Dramatic improvement in survival among adult Brazilian AIDS patients**. *Aids* 2003, **17**(11):1675-1682.
6. Feeney ER, Mallon PW: **HIV and HAART-associated dyslipidemia**. *The open cardiovascular medicine journal* 2011, **5**:49.
7. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ: **Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group**. *Clinical Infectious Diseases* 2003, **37**(5):613-627.
8. Estrada V, Portilla J: **Dyslipidemia related to antiretroviral therapy**. *AIDS reviews* 2011, **13**(1):49-56.
9. Braun SR, Walker H, Hall W, Hurst J: **Clinical Methods, The History, Physical, and Laboratory Examinations**. In.: Butterworth Publishers, Stoneham, MA; 1990.
10. Manjunath C, Rawal JR, Irani PM, Madhu K: **Atherogenic dyslipidemia**. *Indian journal of endocrinology and metabolism* 2013, **17**(6):969.
11. Miller M: **Dyslipidemia and cardiovascular risk: the importance of early prevention**. *QJM: An International Journal of Medicine* 2009, **102**(9):657-667.

12. Obirikorang C, Quaye L, Osei-Yeboah J, Odame EA, Asare I: **Prevalence of metabolic syndrome among HIV-infected patients in Ghana: A cross-sectional study**. *Nigerian medical journal: journal of the Nigeria Medical Association* 2016, **57**(2):86.

13. Ngala R, Fianko K: **Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis**. *African health sciences* 2013, **13**(4):1107-1116.

14. Ankrah DN, Lartey M, Mantel-Teeuwisse AK, Leufkens HG: **Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study**. *BMC infectious diseases* 2017, **17**(1):664.

15. Fisher SD, Miller TL, Lipshultz SE: **Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis**. *Atherosclerosis* 2006, **185**(1):1-11.

16. Umpleby AM, Das S, Stolinski M, Shojaee-Moradie F, Jackson NC, Jefferson W, Crabtree N, Nightingale P, Shahmanesh M: **Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy**. *Antiviral therapy* 2005, **10**(5):663.

17. Fox J, Boffito M, Winston A: **The clinical implications of antiretroviral pharmacogenomics**. 2006.

18. Lazzaretti RK, Gasparotto AS, Sassi MGdM, Polanczyk CA, Kuhmmer R, Silveira JM, Basso RP, Pinheiro CA, Silveira MF, Sprinz E: **Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART**. *The Scientific World Journal* 2013, **2013**.

19. Rios-Gonzalez BE, Luevano-Ortega KE, Saldana-Cruz AM, Gonzalez-Garcia JR, Magaña-Torres MT: **Polymorphisms of seven genes involved in lipid metabolism in an unselected Mexican population**. *Journal of genetics* 2013, **92**(2):114-119.

20. Chang M-h, Yesupriya A, Ned RM, Mueller PW, Dowling NF: **Genetic variants associated with fasting blood lipids in the US population: Third National Health and Nutrition Examination Survey**. *BMC medical genetics* 2010, **11**(1):62.

21. Arnedo M, Taffe P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R: **Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy**. *Pharmacogenetics and genomics* 2007, **17**(9):755-764.

22. Bonnet E, Genoux A, Bernard J, Fauvel J, Massip P, Perret B: **Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy**. *Clinical Chemical Laboratory Medicine* 2007, **45**(7):815-821.

23. Nock NL, Pillai ALC: **Dyslipidemia: genetics and role in the metabolic syndrome**. In: *Dyslipidemia-From Prevention to Treatment*. edn.: InTech; 2012.

24. Kodogo V, Zhou DT, Oektedalen O, Duri K, Stray-Pedersen B, Gomo E: **Apolipoprotein B Gene Polymorphisms and Dyslipidemia in HIV Infected Adult Zimbabweans**. *The open AIDS journal* 2016, **10**:190.

25. Aragonès G, Alonso-Villaverde C, Pardo-Reche P, Rull A, Beltrán-Debón R, Rodríguez-Gallego E, Fernández-Sender L, Camps J, Joven J: **Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism**. *BMC medical genetics* 2011, **12**(1):120.

26. Xu C, Bai R, Zhang D, Li Z, Zhu H, Lai M, Zhu Y: **Effects of APOA5− 1131T> C (rs662799) on Fasting Plasma Lipids and Risk of Metabolic Syndrome: Evidence from a Case-Control Study in China and a Meta-Analysis**. *PloS one* 2013, **8**(2):e56216.

27. Tsai MY, Ordovas JM, Li N, Straka RJ, Hanson NQ, Arends VL, Arnett D: **Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network**. *Molecular genetics and metabolism* 2010, **100**(2):118-122.

28. Fairoozy RH, White J, Palmen J, Kalea AZ, Humphries SE: **Identification of the functional variant (s) that explain the low-density lipoprotein receptor (LDLR) GWAS SNP rs6511720 association with lower LDL-C and risk of CHD**. *PloS one* 2016, **11**(12):e0167676.

29. Kc R, Srivastava A, Wilkowski J, Richter C, Shavit J, Burke D, Bielas S: **Detection of nucleotide-specific CRISPR/Cas9 modified alleles using multiplex ligation detection**. *Scientific reports* 2016, **6**:32048.

30. Thompson ML, Myers J, Kriebel DJO, medicine e: **Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done?** 1998, **55**(4):272-277.

31. Barros AJ, Hirakata VNJBmrm: **Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio**. 2003, **3**(1):21.

32. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C, Cohen M, Young M: **Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens**. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2007, **45**(1):34-42.

33. El□Sadr W, Mullin C, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan S: **Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral□naïve cohort**. *HIV medicine* 2005, **6**(2):114-121.

34. Limas TGd, Pinto GdA, Marcato LM, Coelho DR: **Analysis of the prevalence of dyslipidemia in individuals with HIV and its association with antiretroviral therapy**. *Revista da Sociedade Brasileira de Medicina Tropical* 2014, **47**(5):547-551.

35. Tadewos A, Addis Z, Ambachew H, Banerjee S: **Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study**. *AIDS research and therapy* 2012, **9**(1):31.

36. Kotler DP: **HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients**. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2008, **49**:S79-S85.

37. Panse I, Vasseur E, Raffin□Sanson M, Staroz F, Rouveix E, Saiag P: **Lipodystrophy associated with protease inhibitors**. *British Journal of Dermatology* 2000, **142**(3):496-500.

38. Echevarria KL, Hardin TC, Smith JA: **Hyperlipidemia associated with protease inhibitor therapy**. *Annals of Pharmacotherapy* 1999, **33**(7-8):859-863.

39. Behrens G, Dejam A, Schmidt H, Balks H-J, Brabant G, Körner T, Stoll M, Schmidt RE: **Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors**. *Aids* 1999, **13**(10):F63-F70.

40. Manfredi R, Chiodo F: **Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate**. *Journal of Infection* 2001, **42**(3):181-188.

41. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens ACJ, Wilson JF, Spector T: **Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts**. *Nature genetics* 2009, **41**(1):47.

42. Rotger M, Bayard C, Taffé P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer H, Witteck A: **Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study**. *Circulation: Cardiovascular Genetics* 2009, **2**(6):621-628.

43. Wang N, Tall AR: **Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux**. *Arteriosclerosis, thrombosis, and vascular biology* 2003, **23**(7):1178-1184.

44. Von Eckardstein A, Nofer J-R, Assmann G: **High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport**. *Arteriosclerosis, thrombosis, and vascular biology* 2001, **21**(1):13-27.

45. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA: **A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection**. *Science* 2008, **322**(5908):1702-1705.

46. Jong MC, Hofker MH, Havekes LM: **Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3**. *Arteriosclerosis, thrombosis, and vascular biology* 1999, **19**(3):472-484.

47.   Šeda O, Šedová L: **New apolipoprotein AV: comparative genomics meets metabolism**. *Physiol Res* 2003, **52**:141-146.

48.   Lai C-Q, Tai E-S, Tan CE, Cutter J, Chew SK, Zhu Y-P, Adiconis X, Ordovas JM: **The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore**. *Journal of lipid research* 2003, **44**(12):2365-2373.

49.   Echeverria P, Guardiola M, González M, Vallvé JC, Bonjoch A, Puig J, Clotet B, Ribalta J, Negredo E: **Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients**. *Antiviral research* 2015, **114**:48-52.